PURPOSE Recently, there has been dramatic increase in the diagnosis and pharmaceutical management of common chronic illnesses. Using qualitative data collected in primary care clinics, we assessed how these trends play out in clinical care.
INTRODUCTION

S
pending on prescription drugs in the United States has risen nearly 6-fold since 1990, 1 refl ecting substantial increases in treatment of chronic conditions and subsequent polypharmacy. As many as 45% of Americans have at least 1 diagnosed chronic condition, 2 and 60% of the most prescribed medications were for hypertension, high cholesterol levels, and diabetes. 3 The Centers for Disease Control and Prevention estimates that 11% of the US population and 40% of people older than age 60 take 5 medications or more. 4 Although some studies have documented health benefi ts with multiple medications, 5 adverse drug reactions reported by the Food and Drug Administration tripled between 1995 and 2005, and research fi nds these reactions are the fourth leading cause of death in the United States. In this article, we review several factors underlying these developments and then consider how they play out in chronic illness management in primary care, using data from a qualitative study. Finally, we present a conceptual model to help explain these phenomena and their links to pharmaceutical industry marketing.
FACTORS AFFECTING DIAGNOSIS AND TREATMENT
What might explain the dramatic rise in the diagnosis and treatment of chronic illnesses? Increases in risk factors such as obesity no doubt affect these trends, but more proximate factors should also be considered.
One important factor is a pronounced lowering of diagnostic thresholds for common chronic conditions, notably diabetes and hypertension. Additionally, diagnostic thresholds for hypertension and elevated cholesterol are lower still for people with diabetes, and revised guidelines encourage treatment of predisease conditions, such as prehypertension and prediabetes. [7] [8] [9] [10] As a result, millions of people previously defi ned as healthy now are classifi ed as needing treatment.
11 Table 1 outlines some of these shifts in diagnostic standards and estimates the increase in numbers of cases diagnosed after these changes.
The speed and degree to which these changes affect clinical care are amplifi ed by growth of programs that measure and reward physician performance. Clinicians are increasingly monitored to ensure patients' test numbers remain below given thresholds. 6, [13] [14] [15] Standard quality measures, such as the Healthcare Effectiveness Data and Information Set (HEDIS), 16 which are annually released by the National Committee for Quality Assurance (NCQA), quickly incorporate lower thresholds set by guidelines committees. This practice is especially infl uential on physicians' decision making when combined with pay-for-performance incentive programs. Many insurance companies assess individual clinicians on the basis of whether their patients meet these standards, often paying substantial bonuses 17 that encourage clinicians to respond to marginal test results with aggressive use of pharmaceuticals.
Additionally, prescription drugs often accumulate in what has been called a prescribing cascade, 6, 18 whereby a prescribed drug produces symptoms for which more drugs are prescribed, resulting in polypharmacy and further increasing the risk of adverse drug reactions. The prescribing cascade may be further sustained by clinicians failing to recognize that the drug they prescribed caused the new symptoms, even when the symptoms are well known to be associated with that drug. 19 Lower diagnostic criteria, greater use of quality measures and incentives, and the prescribing cascade all contribute to increased diagnosis of chronic illness and associated polypharmacy. To better understand how these factors operate in primary care, we turn to our study of a group of primary care clinicians and their patients.
METHODS
Two authors (L.M.H. and M.K.) studied primary care clinicians and their patients over a 2-year period (2009) (2010) , focusing on the management of 2 common chronic conditions: type 2 diabetes and hypertension. We set out to examine concepts of racial differences in chronic illness management. As anthropologists, our preconceptions led us to focus on the sociocultural aspects of clinical interactions and communication, and we were less concerned with the specifi c content of treatment approaches. As analysis proceeded, however, the prominence of prescription medications was so pronounced that we were prompted to examine that theme more closely.
We conducted interviews with a purposive sample of 58 clinicians from 44 primary care clinics in Michigan, including various types of practices, both public and private. The clinician sample included physicians, nurse practitioners, and physician assistants who were active in primary care, and excluded full-time academics and administrators. Recruitment strategies included tapping our personal networks, a university preceptor program, and a statewide physicians' research consortium, as well as snowball sampling. We attempted to contact 135 clinicians and interviewed 58; we were unable to reach 25 and determined that 22 did not fi t recruitment criteria, and 30 declined to participate. We observed 107 clinical consultations with 12 clinicians in 6 clinics. In the course of these observations, we recruited a purposive sample of 70 patients being treated for diabetes, hypertension, or both. We interviewed 4 to 7 patients for each of the 12 clinicians we observed. Of the 83 patients invited to be interviewed, 6 did not meet inclusion criteria, 4 could not be scheduled for interviews, and 3 declined.
We developed, piloted, and revised 2 sets of standardized open-ended unstructured questions followed by focused probes, with advice from a cross-disciplinary expert panel. Clinician interviews explored concepts and strategies for managing type 2 diabetes and hypertension. Patient interviews focused on understanding causes, course, and consequences of these diseases, and patients' treatment experiences.
Interviews averaged about 1 hour and were tape recorded and transcribed, yielding approximately 28 pages per interview. All study participants gave informed consent, following institutional review board approved protocols. To ensure anonymity, we have changed all names and personal details in this article.
Interview and observational data were coded into SPSS (SPSS Inc) 20 and NVivo9 (QSR International Pty Ltd) 21 databases by a group of anthropology graduate assistants. As analysis proceeded, increasingly in-depth coding categories were generated, based on emerging thematic patterns. 22 To ensure coding consistency, several research team members reviewed each case, and anomalies or discrepancies were resolved through consensus. Tables 2 and 3 present demographic characteristics of the clinicians and patients interviewed, respectively.
RESULTS
We intentionally overrepresented low-income clinics and minority patients in our sample because we were especially interested in care for these populations.
Polypharmacy
The majority of patients (89%, 62 of 70) reported taking multiple medications, averaging 4.8 prescriptions, with more than one-half (51%, 36 of 70) taking 5 or morethe threshold commonly used to defi ne polypharmacy. 5, 23 How readily prescriptions can accumulate is illustrated by the following case example. 
CHRONIC IL L NES S M A NAGEMEN T
Leroy, a 61-year-old African American man, is a laid-off forklift operator with no health insurance, living on less than $10,000 a year in unemployment benefi ts. Ten years ago, he began taking hypertension medication after a heart attack. Two years ago, he received a diabetes diagnosis, for which he takes metformin. Since starting the hypertension and diabetes medications, he has developed severe indigestion and breathing problems, for which he has been prescribed additional medications. He is currently taking 3 medications for hypertension, 2 for diabetes, 2 for high cholesterol levels, 1 for acid refl ux, and daily doses of aspirin and ibuprofen, and uses an inhaler for chronic bronchitis (chronic obstructive pulmonary disease), for a grand total of 11 medications.
We noted a common scenario: patients began medications after having moderately elevated test results (often at levels considered normal just a few years ago), developed additional symptoms, were found to have values falling outside reference ranges on other tests, and were prescribed more drugs. They were expected to continue these medications permanently: their target laboratory levels could be achieved only through continued use of these drugs.
Emphasis on Medications
Not surprisingly, given the number of medications patients were taking, the clinical consultations we observed focused heavily on choosing and adjusting medications, to the near exclusion of other considerations, such as diet and lifestyle. Below is a consultation typical of those we observed.
Janice, a neatly dressed 35-year-old African American woman, visits her physician for a checkup. The physician comes in the room, reading from her chart: "On your last visit you had an A 1c of 8.1 [%] , and a fasting glucose of 128 [mg/dL]. You're on Lantus insulin, 20 units in the morning." He then looks up at her for the fi rst time, and says, "So, how have you been doing?" She replies: "My sugars have been pretty good-the highest I've had is 137 [mg/dL]"…. The doctor says: "That's okay-we're not too far off." … He asks her what medications she is taking, and she lists 6 prescriptions: 4 for diabetes, 1 for asthma, and 1 for gastritis. "What was your lowest reading?" She answers, "67 [mg/dL]." He asks if she felt woozy or faint, and she says she did not. "That's good-it shows your body is getting used to lower glucose levels." They speak very briefl y about her diet and exercise, he refers her for another test, and he tells her to come back for another checkup in 3 months.
The abundance of pharmaceutical marketing efforts to which these clinicians are exposed may contribute to such heavy emphasis on medications. Nearly threequarters of clinicians (72%, 38 of the 53 who discussed this topic) reported regular contact with pharmaceutical representatives, who provide drug information, free lunches, and free samples. Many (62%, 33 of 53) saw more than 10 representatives weekly. While asserting they take drug representative information with a grain of salt, most (77%, 41 of 53) found the information useful, as this physician assistant's comments illustrate:
A lot of times they will bring in updates on treatment recommendations…. They're slanting it towards their particular product-but it does sometimes give me some new information on the options for certain conditions.
Guidelines
The majority of the clinicians (67%, 39 of 58) mentioned that the diagnostic criteria set out in clinical guidelines were important to their decision making. They clearly believed the guidelines are based on careful review of scientifi c evidence. When referring to specifi c target numbers, clinicians often used phrases such as "the literature tells us" or "research has found."
Only a handful of clinicians (7%, 4 of 58) questioned the clinical soundness of using medications to achieve tight control, as called for by the guidelines. The vast majority expressed no reservations about the appropriateness of the goal numbers for diabetes and hypertension, or about the strategic use of medications to reach those targets. For example, consider this physician's comments about hypertension management:
We're looking for numbers below 140 over 90 [mm Hg]-and for less than 130 over 80 [mm Hg] for our diabetic patients…. Our fi rst-line medications are typically a Dyazide, a Norvasc, or Accupril. Then usually we'll start trying combinations. Some of them may be on all 3. Some of them are on a lot more.
All said they usually combine at least 2 medications for either hypertension or diabetes, and nearly one-half (43%, 25 of 58) regularly combine 3 or more drugs for these conditions. Furthermore, once a patient has a diabetes diagnosis, the goal numbers for hypertension and cholesterol are lower, so additional medications will be prescribed, quickly multiplying prescriptions. A quote from a family practice physician illustrates this phenomenon:
I tell most new diabetics that the sad news is that they're going to be on 5 meds…. That's just what's going to happen because their cholesterol parameters are lower [and] their blood pressure parameters are lower…. It's usually a pretty frank talk: "You have a deadly disease and it's going to kill you. How long you have it is up to you." (Laughs)
Pay for Performance
Pay-for-performance programs may further contribute to the prevalence of polypharmacy in these clinics. In both interviews and observations, clinicians were clearly aware that various institutions-insurance com-panies, employers, and others-were grading their performance. Several (17%, 10 of 58) frankly stated that this motivated them to reach target numbers. As one family physician said: 
Multiplying Prescriptions
A number of cases in our study illustrate the prescribing cascade. 6, 18 Patients on average were taking 4.8 prescriptions, with 3.3 being for hypertension, diabetes, high cholesterol, or some combination thereof. Nearly two-thirds of the patients (60%, 42 of 70) were taking medications for other conditions, but it was diffi cult to parse which were for drug adverse effects. Still, most of those patients (57%, 24 of 42) were taking additional medications for respiratory or gastric symptoms-well-known adverse effects of hypertension and diabetes medications.
Although more than half of clinicians (55%, 32 of 58) said they consider drug adverse effects in selecting medications, few expressed concern about medications causing negative health outcomes. They would simply comment matter-of-factly, "You've got to watch their kidneys with this one," or "I have to check their liver enzymes every now and then."
A number (24%, 14 of 58) discussed the challenge of managing multiple medications, pointing out adverse effects of common medications that may worsen other conditions, requiring even more drugs, for example, β-blockers aggravating asthma symptoms, or antipsychotics elevating blood sugar. When discussing these complicated issues, only 1 clinician mentioned prescribing fewer drugs; all the rest focused on reaching goal numbers by either adding or changing medications.
Patient Well-Being
Although the clinicians in this study were clearly attempting to promote the well-being of their patients by combining drugs to reach optimal test numbers, the experiences reported by patients raise some concerns. Below is an illustration of how heavy reliance on pharmaceuticals can affect patients.
Sherie, a 54-year-old African American woman, is a recently unemployed cosmetologist who lost her health insurance several years ago. She has been taking hydrochlorothiazide and a β-blocker for hypertension for 13 years. Two years ago, she started taking metformin and glipizide after a random glucose reading of 130 mg/dL, as a preventive measure, because of a strong family history of diabetes. After her diabetes diagnosis, her doctor used a lower diagnostic threshold for hypertension and for high cholesterol, and she was prescribed a third antihypertensive and a statin. Sherie is currently taking 8 prescription medications: 3 for hypertension, 2 for diabetes, 1 for high cholesterol levels, and 2 for depression. She has been able to get some of her medications through a county health program that offers generic medications for a $6 copay. But, she explains, even that reduced amount is diffi cult for her: "I used to take my blood pressure pills every other day because every time I turned around I was buying more. And $6 seems like it's not a lot, but it is when you ain't got it." She has recently started receiving 3 medications (Norvasc, Lipitor, and Zoloft) through the Pfi zer patient assistance program, but she continues to struggle and is now coping with serious adverse effects. Her diabetes medications cause diarrhea and bouts of hypoglycemia, which interferes with her ability to leave her home because she must eat and go to the bathroom so frequently. She also had 5 visits to the emergency department in 1 month for excruciating headaches, before they were determined to be an adverse effect of the additional hypertension medication she had been prescribed after her diabetes diagnosis. On the basis of current standards, the clinician classifi ed this patient as healthy, a success story; however, this classifi cation does not address the broader question of her well-being. Getting test numbers into the stipulated range jeopardized her employment and led to repeated hospitalizations and serious fi nancial burden.
Our patient interviews indicated that this situation is far from unique. The fi nancial cost of multiple prescriptions has an important negative impact on many patients. Nearly one-half (49%, 34 of 70) said the price of medications was a challenge. Clinicians did what they could to help control medication costs for patients, such as considering insurance in selecting medications, prescribing generics, giving samples, or helping patients participate in patient assistance programs. Although patients appreciated these efforts, the cost of drugs remained a major concern. The experiences of Karen, an unemployed, 45-year-old white woman with no insurance, highlight these issues. She described a serious hypoglycemic reaction to a lowcost insulin, for which she was hospitalized:
I had gotten really, really sick, and it just wasn't working at all. I went to [my doctor] and I was bawling and I told him: "I'm dying. I'm going to die, this is not working. I don't know what I'm going to do. I don't want to die." He hugged me and he told me that he would hook me up with samples of the Lantus…. And I was doing really well on that…. I've applied for the company to send me the medicine for free because the insurance won't cover it…That will work for a year, and then I guess, I'll be begging [my doctor] to get samples through his offi ce again.
Medication adverse effects are another serious challenge to patients' well-being. Two-thirds of the patients (67%, 47 of 70) reported experiencing symptoms they attributed to their diabetes medications, hypertension medications, or both. This value may be an underestimation of the adverse effects of these drugs: several patients with diabetes (35%, 19 of 55) attributed hypoglycemic symptoms to their disease rather than the diabetes medications, and one-half being treated for hypertension (52%, 29 of 56) blamed headache, dizziness, anxiety attacks, and other symptoms on their hypertension itself rather than the medications. Several patients (13%, 9 of 70) had been hospitalized because of such symptoms, resulting in a medication change.
Although clinicians were aware that many patients struggle with the cost of drugs and with serious adverse effects, these were clearly secondary concerns from the clinicians' perspective. One physician succinctly expressed a sense of resignation about the inevitability of this trade-off in these words:
I've got patients on 4 different medications and their blood pressure is still uncontrolled. We try sending them to the cardiologists, and they say, "Just keep adding stuff because there's really nothing we can do about this."…Some people whose blood pressure that we do get normal again, they don't function very well at all. I'm not sure why.
DISCUSSION
Our study included a relatively small convenience sample of clinicians, so we can draw only tentative conclusions. Before our fi ndings can be generalized to a broader population, they would need to be further examined in a representative sample. Still, the issues raised by this analysis are compelling and require careful consideration.
Through strategic use of an arsenal of pharmaceuticals, the clinicians in this study worked diligently to help their patients attain target blood pressure and glucose levels. We identifi ed a variety of factors contributing to this pattern: lower diagnostic and treatment thresholds, clinician-auditing and reward systems, and the prescribing cascade effect. We also identifi ed challenges to patient well-being resulting from heavy reliance on pharmaceuticals, especially fi nancial costs and adverse drug effects. Although these costs are real and immediate, the potential benefi t of attaining target numbers is abstract: lowering the risk of developing future disease. Why might clinicians be so accepting of these uncertain trade-offs?
One hypothesis is that clinicians are simply applying the best available scientifi c evidence to patient care; however, research regarding the value of these goal levels is far from straightforward. Evidence is accumulating that tight control may not in fact improve patient outcomes, and that harm to patients may actually increase with aggressive management of blood glucose and blood pressure. [24] [25] [26] [27] [28] [29] An alternative hypothesis is that our data refl ect some degree of commercial infl uence over physician prescribing practices. A conceptual model, the inverse benefi t law, proposed by Brody and Light, 13 suggests how this might occur. Intended as a conceptual heuristic rather than a mathematically precise model, this law holds that the benefi tto-harm ratio of a medication varies inversely with how aggressively the drug is marketed by industry. Pharmaceutical marketing prompts physicians to prescribe more drugs to more patients, with less and less chance of deriving long-term benefi t, while exposing that nowmuch-larger drug-taking population to increased risk of adverse drug reactions. 30 Critics have documented many deleterious health effects resulting from pharmaceutical industry marketing strategies.
6,17,31-35 Applbaum 36, 37 argues that drug fi rms' marketing efforts focus on controlling entire drug "channels," the complex routes that drugs follow from manufacture to ingestion by patients. The treatment of diabetes and hypertension are areas where the industry may have effectively captured much of the channel. The very way practitioners think about these conditions promotes drug sales, by prioritizing abstract hoped-for patient benefi ts, while downplaying increased risks. 14, 17, 38 We found numerous instances of physicians acting in ways that the inverse benefi t law would predict.
Lower diagnostic thresholds have resulted in large increases in the number of candidates for treatment, with an estimated 10 million additional people being treated for diabetes 39 and 22 million for hypertension. 40, 41 These increases have 2 major implications for patient health. First, because these new cases have much less severe disease, their likelihood of benefi tting is low (ie, the number needed to treat is high), but everyone has a roughly equal chance of experiencing adverse reactions, so the total burden of adverse reactions increases considerably. Second, the new cases have test values closer to normal when they begin treatment, so their risk for iatrogenic hypoglycemia or hypotension is higher than that in patients with more severe illness. Figure 1 presents a schematic representation of these relationships for the case of type 2 diabetes, illustrating the inverse association between potential benefi t and potential harm as diagnostic thresholds decrease, increasing the number of people taking medications for these conditions (also see the discussion of Welch et al 11 on the ratio of potential net harm to net benefi t for a variety of conditions, when diagnostic criteria are changed).
How might the industry that so dramatically profi ts from lowered treatment thresholds be affecting their establishment and promotion? We can identify a number of potential mechanisms, but because these infl uences are intentionally obscured, our argument is speculative.
The pharmaceutical industry infl uence goes beyond marketing directly to physicians. The industry has frequently been shown to systematically generate and publish research fi ndings that promote their drugs. [31] [32] [33] [34] [35] 42 The industry may also infl uence the establishment of clinical standards. It would be imprudent to claim that the industry dictates these standards; however, the committees and organizations setting the standards often have substantial pharmaceutical industry support and include many individuals with industry ties. 14, 43, 44 As we saw, increasing use of grading and reward programs may amplify clinician interest in reaching goal numbers. Although such programs encourage clinicians to aggressively use pharmaceuticals to reach target numbers, [45] [46] [47] there is no consensus on whether they actually improve overall outcomes. 48 Those who prescribe more judiciously, prioritizing patient benefi t over marginal improvements in test values, may actually be penalized by this system.
An obvious industry infl uence is the impressive presence of the drug representatives in the practices included in our study. A recent national survey reported that 87% of physicians have regular contact with these marketing professionals. 49 Given that the industry spends an estimated $53 billion annually on marketing pharmaceuticals to US physicians, 50 one must assume that these marketing efforts have at least some infl uence on prescribing practices. The value of programs offering low-cost or free medications may seem obvious, but on closer examination, the inverse benefi t law again seems to be at play. Although these programs get brand-name medications to lowincome patients, they may also divert physicians from equally effective, more affordable generics. Even more concerning, they effectively draw patients into a long-term market for drugs they cannot afford.
As would any clinician, those interviewed for this study wanted to offer quality care, meet practice standards, and prevent serious downstream complications. But in adhering to authoritative medical guidelines, they are diagnosing and treating test levels closer to normal and prescribing more and more drugs, while unaware of the infl uence that the pharmaceutical industry may have had on establishing the standards and practices they follow. 34, 36, 49 The infl uence of the pharmaceutical industry on the marketing of medications for these chronic illnesses appears very successful. Although quite benefi cial for industry profi ts, the consequences may include worsening health and increased risks from medications for patients. 6, 13 A full discussion of what might be done to reverse these troublesome trends is beyond the scope of this article. At a minimum, we urge policies excluding individuals or organizations with fi nancial confl icts of interest from involvement with guideline-writing panels. The presumption that mere disclosure resolves such confl icts must be rejected. 51, 52 Physicians should be discouraged from seeing drug representatives, through programs such as the Unbranded Doctor program of the National Physicians Alliance. 53 Payfor-performance plans should be monitored closely for evidence of unintended negative effects on patients. Together, such policy changes may slow the disturbing trends our fi ndings illustrate. 
